The Filing Desk

Mesa Laboratories vs 10x Genomics

Mesa Laboratories MLAB · 10x Genomics TXG · Life Sciences Tools & Services

10x Genomics reported revenue of $643 million in fiscal 2025, 2.6 times Mesa Laboratories' $249 million in fiscal 2026. Mesa Laboratories' revenue grew 3.4% in its latest year, and 10x Genomics' grew 5.2%. Mesa Laboratories had an operating margin of 7.4%, against -9.5% at 10x Genomics. Free cash flow was $40 million at Mesa Laboratories and $130 million at 10x Genomics. Their fiscal years end in different months (March 31 and December 31), so the periods don't line up exactly.

Side by side

Mesa Laboratories10x Genomics
Latest fiscal yearFY2026, Mar 31, 2026FY2025, Dec 31, 2025
Revenue$249M$643M
Revenue growth3.4%5.2%
Revenue growth a year, last 5 years13.2%16.6%
Gross margin63.5%69.0%
Operating margin7.4%−9.5%
Net margin2.7%−6.8%
Free cash flow$40M$130M
Free cash flow margin15.9%20.2%
Return on capital4.8%−16.3%
Net debt to EBITDA1.0x—
Dividends and buybacks$4M$0M
Change in diluted share count2.7%3.6%
Last close$139.01$58.19
P/E at the last close120.9×—
Insider trades, last 12 months—sold $18.8 million
Piotroski F-score8 of 95 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Mesa Laboratories10x Genomics
Operating margin
Percent of revenue
Mesa Laboratories10x Genomics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Mesa Laboratories10x Genomics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Mesa Laboratories and 10x Genomics pages.